ClinicalTrials.gg
WithdrawnNCT05085574Updated Oct 10, 2023

Leidos-Enabled Adaptive Protocol for Clinical Trials (LEAP-CT) in Hospitalized Patients With COVID-19 (Addendum 1)

A Phase 2 interventional study of Famotidine and Celecoxib in 2019 Novel Coronavirus Disease, 2019 Novel Coronavirus Infection and 2019-nCoV Disease, sponsored by Leidos Life Sciences. Withdrawn. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-10-10.

Sponsored by Leidos Life Sciences · Phase 2, Interventional, and Treatment

Why this study was withdrawn
COVID environment, lack of site confidence to enroll subjects, sites not suited to study procedures, decline of potential inpatient subjects at site

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
0
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 10 studies testing famotidine in COVID-19 — none open to participants now, 1 under way, none of them phase 3. Famotidine · COVID-19.

Enrollment
8th of 10
0 · median 5
Started
2023
the only one that year
Phase 2
6 of 10
none open now
Registered
7th of 10
by date
Lead sponsor
3 of 10
Leidos Life Sciences

Among the 10 studies testing famotidine in COVID-19, this one is the 8th largest by enrollment, is the only one that started in 2023, is one of 6 in phase 2, and was the 7th registered.

COVID-19

7,994 studies on the registry are indexed under COVID-19; 467 are open to participants now.

Browse COVID-19 studies →

Open to participants now

None of the 10 studies testing famotidine in COVID-19 is open now. The open studies under COVID-19, anywhere →

Where they have run

About famotidine

Famotidine: first FDA approval 1986 (PEPCID). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 356 COVID-19 studies recruiting now, 206 (58%) set no upper age limit and 83 (23%) stop at 75 or younger; 91 take children under 18; 135 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 10 studies testing famotidine in COVID-19 as a file.
02

Study summary

This study is designed to test the efficacy and safety of combinations of two well-understood agents - famotidine and celecoxib in patients hospitalized with moderate-to-severe COVID-19 (based on World Health Organization [WHO] Ordinal Scale for Clinical Improvement). Both famotidine and celecoxib separately demonstrate clinical activity in mitigating COVID-19 disease symptoms or severity, and appear to have separate and complementary mechanisms of action.

Read the detailed description

Participants will be randomly assigned, in a 1:1 ratio, to one of two regimens, with 202 subjects per group as follows:

Group 1 (study product) subjects will receive 80 mg famotidine by mouth (PO) 4 times per day (QID) + 400 mg celecoxib as a first dose, followed by 200 mg celecoxib PO, 2 times per day (BID), for 5 days. Following this 5-day period, subjects will continue their famotidine treatment for an additional 9 days.

Group 2 (reference therapy) subjects will receive matching placebos QID and BID, for 5 days. Following this 5-day period, subjects will continue to receive matching famotidine placebo, QID, for an additional 9 days.

Safety, efficacy and pharmacokinetics of famotidine and celecoxib will be evaluated.

All participants will receive the standard of care (SOC), which typically consists of remdesivir, decadron (dexamethasone), lovenox, tociluzimab, and convalescent plasma. At the discretion of the investigator, study treatment can be stopped and dexamethasone initiated in study participants who require supplemental oxygen (WHO 5) as outlined in the NIH COVID-19 Treatment Guidelines. Investigators are required to stop study treatment and initiate dexamethasone, as indicated in participants who require high-flow oxygen (WHO 6), non-invasive ventilation (NIV; WHO 6), invasive mechanical ventilation (WHO 7-8) or extracorporeal membrane oxygenation (ECMO; WHO 9), in accordance with the NIH COVID-19 Treatment Guidelines. The NIH COVID-19 Treatment Guidelines recommend against the use of dexamethasone only in hospitalized patients not requiring supplemental oxygen (WHO 4).

03

Conditions studied

  • 2019 Novel Coronavirus Disease
  • 2019 Novel Coronavirus Infection
  • 2019-nCoV Disease
  • 2019-nCoV Infection
  • COVID-19 Pandemic
  • COVID-19 Virus Disease
  • COVID-19 Virus Infection
  • Covid19
  • Coronavirus Disease 2019
  • SARS-CoV-2 Infection
  • SARS-CoV-2 Acute Respiratory Disease
  • COVID-19

Browse trials for

Keywords

  • COVID-19
  • COVID
  • COVID19
  • SARS-CoV-2
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female participants must be at least 18 years of age, inclusive, at the time of signing the form.
  • Confirmed COVID-19 or symptom onset within 7 days of hospitalization, as shown by medical history, physical exam, and laboratory tests (PCR), and who have been hospitalized for COVID-19 at WHO Grade 4-5.
  • use by men or women should be consistent with Appendix 4 of the Master Protocol (LDOS-21-001).
  • Capable of understanding and providing a signed informed consent form.
  • Reliable access to the internet.

Exclusion criteria

Exclusion Criteria:

Participants are excluded from the study if any of the following criteria apply:

  • Pregnant or breastfeeding
  • History of
  • Ongoing treatment that cannot be temporarily discontinued during the study: anti-inflammatory treatment (nonsteroidal anti-inflammatory drugs [NSAIDS]);; antimalarials; antiarrhythmics; tricyclic antidepressants; natalizumab; quinolones; macrolides; and agalsidase alfa and beta

    1. drugs dependent on gastric pH for absorption, e.g., dasatinib, delavirdine, mesylate, cefditoren, and fosamprenavir;
    2. tizanidine (CYP1A2) substrate;
    3. drugs that interfere with hemostasis (e.g., warfarin, aspirin, selective serotonin reuptake inhibitors [SSRIs]/serotonin norepinephrine reuptake inhibitors [SNRIs]);
    4. angiotensin converting enzyme (ACE) inhibitors, angiotensin receptor blockers (ARB), or beta-blockers;
    5. diuretics;
    6. digoxin
  • Ongoing famotidine, celecoxib, or other COVID-19 clinical treatment(s) within the past 30 days or current participation in another investigational clinical trial
  • History of
  • History of asthma, urticaria, or other allergic-type reactions after taking aspirin or other NSAIDs
  • Rejection of participation at the discretion of the Principal Investigator or Sponsor
  • Any for famotidine or celecoxib treatment:

    a. Famotidine or celecoxib ; b. Retinopathy, visual field or visual acuity disturbances; c. History of cardiovascular disease, such as congestive heart failure, , bradycardia (\<50 bpm), ventricular tachycardia, other arrhythmias, as determined at screening (ECG) or medical history; d. Potassium \<3 mEq/L (milliequivalent/liter) as determined at Visit 1; e. (AST) or alanine aminotransferase (ALT) >5 upper normal limit, as determined at Visit 1; f. Previous myocardial infarction; e. Myasthenia gravis; h. Psoriasis or porphyria; i. Glomerular clearance, 60 mL/min; j. Previous history of severe hypoglycemia; k. Known or suspected to be poor CYP2C9 metabolizers based on genotype or previous history or experience with other CYP2C9 substrates, such as warfarin and phenytoin; l. Moderate or severe hepatic impairment, e.g., Class B or C.

Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
0 participants (actual)

Study arms

  • Experimental
    Group 1 (Study Product)

    Subjects will receive 80 mg famotidine (PO) QID and 400 mg celecoxib as a first dose, followed by 200 mg (PO) BID celecoxib, for 5 days. Following this 5-day period, subjects will continue their famotidine treatment for an additional 9 days.

    Drug: Famotidine · Drug: Celecoxib

  • Placebo comparator
    Group 2 (Reference Therapy)

    Subjects will receive matching placebos QID and BID, for 5 days. Following this 5-day period, subjects will continue to receive matching famotidine placebo, QID, for an additional 9 days.

    Drug: Placebo

Interventions

  • 80 mg tablet, QID for 14 days

    Also known as: Pepcid

  • 400 mg (initial dose), then 200 mg capsule, BID for 5 days

    Also known as: Celebrex

  • DrugPlacebo

    tablet, QID for 14 days; capsule, BID for 5 days

06

What researchers measure

Primary outcomes

  1. Time-to-event to achieve WHO level ≤3

    Evaluation of the time-to-event to achieve a WHO level score ≤3

    Time frame: 30 days

  2. Death rate

    Evaluation of the time-to-event where all-cause mortality occurs

    Time frame: 30 days

Secondary outcomes

  1. Hospital discharge to chronic palliative care

    Measured incidence of hospital discharge to chronic palliative care

    Time frame: 30 days

  2. Hospital discharge with no additional medical care

    Measured incidence of hospital discharge with no additional medical care required

    Time frame: 30 days

  3. Related adverse events (AEs) and serious adverse events (SAEs)

    Measured incidence of related AEs and SAEs

    Time frame: 90 days

  4. Study discontinuation due to related AEs or SAEs

    Measured incidence of study discontinuation due to related AEs or SAEs

    Time frame: 90 days

Other outcomes

  1. Pharmacokinetic (PK) endpoint-Assess area under the curve

    Measure area under the curve (AUC) for famotidine and celecoxib combination in 10 patients per group

    Time frame: 14 days

  2. Pharmacokinetic (PK) endpoint-Assess time to maximum plasma concentration

    Measure time to maximum plasma concentration (tmax) for famotidine and celecoxib combination in 10 patients per group

    Time frame: 14 days

  3. Pharmacokinetic (PK) endpoint-Assess maximum serum concentration

    Measure maximum serum concentration (Cmax) for famotidine and celecoxib combination in 10 patients per group

    Time frame: 14 days

  4. Exploratory endpoint-Incidence of symptom reduction

    Cumulative incidence of clinically significant symptom reduction (severity and duration) using COVID-19 Symptom Score

    Time frame: 14 days

  5. Exploratory endpoint-Incidence of clinical improvement

    Cumulative incidence of clinically significant symptom reduction (severity and duration) using WHO Ordinal Scale for Clinical Improvement

    Time frame: 14 days

  6. Special Assessment - High-resolution computed tomography (HRCT), 20 patients/group, change from baseline

    HRCT scan of the chest

    Time frame: Study Day 1 (baseline), Day 16 (discharge), 30 days after first dose, and 90 days after first dose

  7. Special Assessment - Total lung capacity (TLC), 20 patients/group, change from baseline

    TLC

    Time frame: Study Day 1 (baseline), 16 (discharge), 30 days after first dose, and 90 days after first dose

  8. Special Assessment - Prostaglandin E2 (PGE2), 20 patients/group, change from baseline

    PGE2 testing

    Time frame: Study Day 1 (baseline), 16 (discharge), 30 days after first dose, and 90 days after first dose

  9. Special Assessments - Urinalysis, 20 patients/group, change from baseline

    Urinalysis

    Time frame: Study Day 1 (baseline) and 16 (discharge)

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: Undecided — It is not yet known if there will be a plan to make individual participant data (IPD) available.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Feb 2023 to primary completion in Feb 2023, 0 months.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 7, 2021
First posted
Oct 20, 2021
StartActual
Feb 7, 2023
Primary completionActual
Feb 7, 2023
CompletionActual
Feb 7, 2023
Last update
Oct 10, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 10, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05085574
Lead sponsor
Leidos Life Sciences
Collaborators
United States Department of Defense
Responsible party
Sponsor
First posted
Oct 20, 2021
Start date
Feb 7, 2023
Primary completion
Feb 7, 2023
Completion
Feb 7, 2023
Last update
Oct 10, 2023

Study contacts

Tilly Lawrence, BSN, RN
study director · Leidos, Inc.

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is withdrawn, as verified in Oct 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Famotidine · Celecoxib

Start the discussion